Purpose Pediatric prolactinomas are rare, especially in children under 14 years of age. In this study, we evaluated the clinical presentation and microsurgical outcome of prolactinomas in prepubertal children. Methods Nine patients with prolactinomas who had undergone surgical removal of the tumor before the age of 14 years were included in this retrospective study. Data on their clinical presentation, medications, physical and laboratory evaluations, radiological findings, and long-time follow-up were obtained from their medical records. Results The main presenting symptom in the four female patients was galactorrhea (n=4, 100 %), whereas the five male patients most commonly presented with headache (n =4, 80 %) and growth retardation (n=3, 60 %). Six (66.6 %) of the patients who had undergone transsphenoidal surgery were medication-free postoperatively. In three (33.3 %) patients with giant adenomas, complete resection of the tumor was not achieved. One (11.1 %) patient received radiotherapy after failed surgical and medical treatment. Postoperatively, electrolyte disturbances occurred in five (55.6 %) patients, diabetes insipidus in two (22.2 %), and thyroid dysfunction in two (22.2 %). These complications resolved spontaneously. During follow-up, growth and puberty were usually normal. Conclusions Tumor compressive symptoms and/or gonadal and growth arrest may be the primary clinical presentations of pediatric prolactinoma. Patients who are not candidates for dopamine agonist therapy are best treated surgically, based on the low mortality and high cure rates. Hypopituitarism is a rare complication and may resolve spontaneously. Following successful treatment of a prolactinoma, growth and puberty in these children are normal.
Introduction
Pituitary adenomas are relatively infrequent in children, with a prevalence of <3 % of all intracranial tumors [17, 32] . Previous epidemiological studies have shown that prolactinomas account for approximately half of all pituitary adenomas, followed by adrenocorticotropic-hormone-secreting adenomas and growth-hormone (GH)-secreting adenomas [9, 19] . However, prolactinomas in children, especially prepubertal children, have been described in only a few reports. Consequently, the diagnosis and treatment of these tumors are often challenging. In this study, we report the etiology, clinical presentation, response to medical and surgical treatment, and long-term follow-up of nine pediatric (≤14 years of age) patients with prolactinomas who underwent surgical treatment in our hospital from 1993 to 2013.
Materials and methods

Patients and experimental protocol
Five male and four female patients between the ages of 7 and 14 years who, because of dopamine agonist (DA) resistance, underwent surgery for prolactinomas in the Neurosurgery Department of Peking Union Medical College Hospital from 1993 to 2013 were studied retrospectively. The cutoff age was 14 years old because at that age, most children are prepubescent. Prolactinomas were defined as serum prolactin (PRL) levels >100 ng/ml as determined endocrinologically, the presence of a tumor mass effect as seen on enhanced magnetic resonance imaging (MRI) performed preoperatively, and pathological confirmation postoperatively. Children with primary hypothyroidism, a psychiatric history, iatrogenic hyperprolactinemia, and polycystic ovary were excluded. Clinical presentation, associated diseases, medications, physical and laboratory evaluations, and radiological findings were recorded using the data in the patients' medical records. As in previous studies, bromocriptine resistance was defined as the failure to achieve normal PRL levels or a ≥50 % reduction in tumor size despite the administration of >15 mg of bromocriptine/day for at least 3 months [18, 28] . A prolactinoma with a diameter <10 mm was referred to as micro-prolactinoma. Macro-prolactinoma was defined as a tumor with a diameter between 10 and 30 mm. A prolactinoma >30 mm was defined as giant prolactinoma.
Follow-up
Follow-up was scheduled to begin immediately after the operation. Routine follow-up MRIs were performed at least semi-annually for the first 3 postoperative years. An evaluation of all pituitary functions was performed immediately after surgery and then at periodic intervals. Postoperative hypopituitarism was defined as newly abnormal anterior pituitary function or the need for long-term hormone replacement. Data on pituitary hormone levels and clinical manifestations were obtained from the medical records of the outpatient department.
Statistical analysis
PRL levels between males and females were compared using a non-parametric t test. Differences were considered statistically significant at p<0.05. All analyses were performed using Graphpad Prism 6.
Results
Clinical presentation
Clinical information on the nine patients is presented in Table 1 . Among the four females, the age at menarche was recorded in only one (patient no. 2); therefore, the main presenting symptom in female patients was galactorrhea (100 %). Among the five males, headache and/or visual field defects were the main presenting symptoms in four (80 %). Growth and/or puberty arrest was observed in three (60 %) male patients. Two of these patients had a height below the average for their age (<−2SD), and one (no. 9) presented with growth retardation (<−3SD below the normal height at that age). By contrast, all female patients had normal heights and puberty development, although in one patient (no. 1), body mass index exceeded the 97th percentile (Table 1 [22, 23] ).
Hormonal and radiological findings
The MRI images demonstrated two giant, one micro-, and one macro-prolactinoma in the four female patients and three giant and two macro-prolactinomas in the five male patients. Serum PRL concentrations ranged from 281 to 2011 ng/ml in the female patients and from 378 to 14,222 ng/ml in the male patients. However, because of the small sample size, the findings did not reach statistical significance (t test, p=0.2591, Fig. 1 ). Overall, the mean PRL level was higher in males than in females (4565 vs. 722.5 ng/ml). In addition, the mean PRL level was higher in patients with giant adenomas than in those with macro-adenomas (4804.5 vs. 470.133 ng/ml). Only patients with drug-resistant prolactinomas necessitating surgical treatment were included in this study. As shown in Table 2 , surgery resulted in a significantly high cure rate, with 66.6 % of the patients who underwent transsphenoidal surgery for prolactinomas being medication-free at a follow-up of 3-13 years (median follow-up time, 8.17 years) ( Fig. 2) . In our three patients with giant adenomas (nos. 4, 5, and 6), complete tumor resection was not possible because of invasiveness or firmness. In patient no. 4, surgery decreased the PRL level from 467 ng/ml, achieved with 15 mg bromocriptine/day, to 107 ng/ml immediately, allowing a lower bromocriptine dose (5 mg/day) for the continued suppression of PRL to normal levels. During the 3 years of follow-up of this patient, her symptoms at diagnosis, primarily headache and galactorrhea, disappeared and menstruation was regular. Patient no. 6, who had an extremely high PRL level of 14,222 ng/ml and an invasive giant adenoma, surgery resulted in a sharp decrease of the PRL level, to 358 ng/ml (Fig. 3 ). Because the preoperative mass effect was improved by the surgical treatment, he was maintained on 15 mg bromocriptine/day and was closely followed. Compression symptoms such as headache or visual field defect were not reported, but the PRL level continued to fluctuate around the upper limit of normal. For patient no. 5, a small residual lesion was detected after surgery, which probably accounted for the postoperative increase in PRL levels. Postoperative treatment first with 15 mg bromocriptine/day and then with 20 mg bromocriptine/day reduced the PRL level from 511 to 409.8 ng/ml. However, 6 months after surgery, the PRL level had increased dramatically, to 1007.2 ng/ml, and radiotherapy was therefore administered. In our patient no. 5, who received conventional radiotherapy (25 doses of 32.4 Gy) after the failure of medication and surgery, the PRL level decreased to 732.7 ng/ml; with adjuvant of 11.25 mg bromocriptine/day, the PRL level was further suppressed to 141.8 ng/ml. Electrolyte disturbances were the most common postoperative complication, occurring in five (55.6 %) patients. Other postoperative complications included diabetes insipidus (n=2, Fig. 1 Baseline PRL levels in different genders. Although the mean PRL level was higher in male group, because of small samples, no statistical difference was found between these two groups (t test, p=0.2591) 22.2 %) and thyroid dysfunction (n=2, 22.2 %). All of these complications resolved spontaneously. Visual field defects occurring preoperatively were resolved postoperatively. The longterm follow-up (6, 8, and 3 years, respectively) of the three patients who presented with growth retardation (nos. 6, 7, and 9) demonstrated major improvements in growth development, even in the patient (no. 6) without total resection of the tumor.
Discussion
The majority of pituitary adenomas in children are functional adenomas, with prolactinomas being the most common [9] . Among the 54 pituitary adenomas occurring in children under 14 who were treated at our hospital, pediatric prolactinomas accounted for 16.7 %, and among the 1148 prolactinoma patients seen at our institution from 1993 to 2013 for 0.78 %. However, there are few published studies on the clinical presentation, individualized treatment, and long-term outcome of pediatric prolactinoma patients, especially those under 14 years of age and younger. Prolactinomas most often occur in females [8] , but our series, consisting of four females and five males, was too small to be evaluated statistically. Clinical presentations in these nine patients varied according to age, sex, PRL level, and tumor size. Headache, impaired vision, and galactorrhea are the most common presenting symptoms of prolactinoma [9, 10, 14, 19] . In our study, the male patients had a higher prevalence of macro-adenomas or giant adenomas (100 vs. 75 % in females) and therefore usually presented with tumor mass effects, such as headache (80 vs. 25 % in females) and impaired vision (60 vs. 0 %). Because most of our female patients under 14 years old had not yet reached menarche, we could not determine whether they had primary amenorrhea. Despite a disagreement in the literature as to whether GH deficiency is a common finding in children with Fig. 2 Postcontrast-enhanced T1-weighted in coronal (a) and sagittal (b) MRI of case no. 9 before operation which shows a macro-prolactinoma. Coronal (c) and sagittal (d) postcontrast enhancement T1-weighted MRI at last follow-up (3 years after operation) which shows the disappearance of tumor prolactinomas, because of tumor compression [10, 27, 36] , in our series, stunted growth was an important clinical presentation. According to their medical records, three (60 %) male patients had growth failure, including one in whom growth failure was the main clinical manifestation. Unfortunately, none of the patients underwent a specific examination such as a GH stimulation test; thus, it was unclear whether they had a GH deficiency. This is an important aspect that should be addressed in future studies of pediatric prolactinoma patients. Besides growth retardation, hyperprolactinemia may affect hypothalamic-gonadotropic activity, resulting in a deficiency of the pituitary-gonadal axis and therefore a delay of puberty [31] . In China, an early diagnosis of abnormal sexual development caused by prolactinomas is difficult because some Chinese parents do not monitor the sexual development of their children. Therefore, the frequency of prolactinomas diagnosed in Chinese children might be underestimated because the symptoms fail to raise parental suspicion, even in children who are symptomatic for many years.
Children with symptoms suggesting prolactinoma should undergo a complete pituitary hormone evaluation as part of the diagnostic examination. In adult patients, baseline PRL levels correlate well with the size of the prolactinoma, which is also largely the case in children [9] . Although the number of patients in our study was too small to determine statistical significance, our data tended to be consistent with these studies.
Previous studies on adult, asymptomatic patients with untreated micro-prolactinomas demonstrated that the significant growth of these tumors was rare [9] . Nevertheless, children with prolactinomas are usually diagnosed with obvious clinical presentation, and treatment is therefore essential. In adult patients [25] , the purpose of therapy is to reduce the size of the tumor, control PRL levels, and restore visual or cranial nerve function. In pediatric patients, the restoration of normal growth and development should be emphasized. Medical therapy with DAs, even for macro-adenomas, was shown to be effective in normalizing PRL levels and in shrinking tumor size in the majority of adult patients [25] . In children and adolescents, medical therapy has also been used successfully [1, 12, 30] . In China, bromocriptine is the only commercially allowed DA that can be used in the treatment of prolactinomas; thus, children with prolactinomas in our hospital were given bromocriptine as the primary therapy. Bromocriptine suppresses pituitary mitosis and induces apoptosis, thereby depressing PRL levels and diminishing tumor size [37, 38] . Moreover, the favorable response obtained in pediatric prolactinoma patients with a GH secretion deficiency implies that bromocriptine monotherapy is an effective primary therapy, as also reported in the literature [9, 30] .
However, bromocriptine treatment is notorious for its side effects, including vomiting, nausea, and postural hypotension. The poor response or secondary resistance to the drug seen in some patients also poses a therapeutic challenge. In China, parents of pediatric prolactinoma patients are concerned about their children's long-term exposure to the drug, which has resulted in poor compliance. Appropriate treatment with DAs in these patients may have prevented surgery. However, as noted in the literature [25] , in addition to the risk of drug resistance and problems with the potential side effects of bromocriptine, surgery should be considered in children with hydrocephalus or cerebrospinal fluid leak. Surgery is not our first-line recommendation, although it is as safe in children as in adult patients and transsphenoidal surgery can be achieved with minimal invasiveness [4, 24, 33] . The goal of surgery is to achieve complete tumor resection while preserving normal pituitary function. In our experience, the most important issue in children is the small size of the nares and the lack of full pneumatization of the sphenoid sinus. To address this problem, dedicated pediatric instrumentation, such as a narrower and shorter endonasal speculum, would facilitate surgery. Preoperative computed tomography and standard navigational MRI would offer more specific visualization of the anatomy in the sphenoid region. Intraoperative fluoroscopy by X-ray may also be useful. Although the exposure of surgical field is better by endoscopic approach, we believe that transnasal microsurgical approach and transnasal endoscopic approach are both well, surgical technique and extensive experience of a surgeon are more important.
Prior to surgery, physicians should consider the impact of pretreatment with bromocriptine, as some studies have shown that it shrinks the tumor and facilitates surgical resection [13, 20] ; however, according to others, preoperative bromocriptine results in adverse effects on tumor consistency that impede prolactinoma resection [16] . Our own experience supports the use of preoperative bromocriptine treatment in patients who are sensitive to the drug, especially because the shrinkage of an invasive prolactinoma may facilitate its complete resection.
Follow-up MRI studies were usually performed within 3 months postoperatively. Gross total resection was defined as no residual tumor on postoperative MRI. Surgery has been shown to allow the removal of pituitary adenomas in adults and children with few complications and near-zero mortality [33] . In fact, the definition of cure in patients with prolactinomas is complete surgical removal of the tumor and no recurrence of hyperprolactinemia following the withdrawal of medical therapy. Colao et al. showed that primary surgical treatment can lead to a high recurrence rate and associated pituitary hormone deficiencies [10] . Eren et al. found that surgery without extensive resection could protect pituitary function but leads to a high recurrence rate, as six of their seven patients with macro-prolactinomas required postoperative DA therapy [12] . Our experience recommends a preliminary, thorough exploration of the anatomic location of the normal pituitary. Generally, pituitary adenomas are gray or purple bean-curd-like tissues; also, most of these tumors are soft and are therefore easily resectable. Their features contrast with those of normal pituitary tissues, which are usually pale yellow and firmer than pituitary adenomas. Additionally, the normal pituitary gland is usually located above the tumors and is easily identified. In tumors that are difficult to distinguish, pathological examination is helpful. Blind resection is inadvisable because of possible damage to the normal pituitary. For patients with failed surgical and medical treatment, radiotherapy has been recommended as a treatment option [5] , even though aggressive therapy may increase the risk of severe obesity, diabetes insipidus, and multiple hypothalamicpituitary deficits. Additional radiotherapy-related complications include memory defects, emotionally labile behavior, and impaired social and cognitive functioning, which severely compromise the quality of life [11, 26, 29] . More importantly, patients with prolactinomas treated with radiotherapy have a much higher mortality, and the normalization of PRL levels by radiotherapy is far from certain [19, 24, 35] . Successful normalization of PRL is rare, even in adult patients with prolactinomas [3] . Most of the adult patients in Gillam et al.'s review presented after the failure of medical treatment and/or surgery, with an overall normalization rate for the entire series of conventional radiotherapy versus single-dose stereotactic radiotherapy alone of 34.1 versus 31.4 % [3, 8, 9, 15] . We therefore recommend that the use of radiotherapy in the pediatric population should be strictly limited, with careful assessment of whether the potential positive effects of radiotherapy outweigh the very possible complications. Patients with residual pituitary adenomas with cavernous sinus invasion might be good candidates for radiotherapy, because the cranial nerves in the cavernous sinus are radio-resistant [6] .
A previous study showed that PRL levels decrease on postoperative day 1 (POD 1) if surgery is effective and that the immediate postoperative PRL levels are of strong prognostic value [2] . In that study, patients with micro-adenomas and PRL levels <10 ng/ml on POD 1 had a 100 % cure rate in the long-term follow-up whereas those with macro-adenomas had a 93 % cure rate. However, Thomson [34] demonstrated that hyperprolactinemia can recur even if the postoperative PRL level is normal. According to our study, as shown in Table 2 , five of the six patients in whom complete tumor resection was achieved had low postoperative PRL levels (0.48-4.8 ng/ml). None of these patients experienced tumor recurrence regardless of the prolactinoma type (micro, macro, or giant). In patient no. 9, in whom total resection of the macro-adenoma was achieved, the postoperative PRL level was 24.3 ng/ml and thus far there is no evidence of relapse. Nonetheless, continued follow-up is warranted because relapses can occur even after 10 years postoperatively [10, 34] , although the first few years after surgery are considered the most important period for relapse.
Diabetes insipidus, cerebrospinal fluid leak, and anterior pituitary insufficiency are the most common postoperative complications [7] . These complications usually appeared in the first few days after surgery, especially on POD 1, because of the transient stimulatory effects of surgery on posterior pituitary function, but all of them quickly resolved. Endocrine examinations, including thyroid function, were an essential aspect of the postoperative examination. Thyroid dysfunction was usually seen in the first 3 months because surgery also stimulates the anterior pituitary but, again, in most cases, the symptoms soon resolved. None of our patients had cerebrospinal fluid leak or hemorrhage, which we attribute to careful surgical technique and our extensive experience. Thus, for patients who are not candidates for DA therapy, transsphenoidal surgery is a highly effective method in the management of prolactinomas, despite the risk of brief postoperative complications.
Many challenges remain in the treatment of pediatric prolactinomas because some of the tumors are extremely large and invasive and PRL levels are very high. In addition, because the volume of the normal pituitary gland increases by approximately 70 % during pregnancy [21] , whether females who as children underwent surgery for prolactinomas will experience problems related to disease recurrence during pregnancy is unclear. Also, whether these patients will develop fertility problems has not been determined. None of our female patients have had children.
Conclusion
Prolactinomas are the most common functional pituitary adenoma. Tumor compressive symptoms and/or gonadal and growth arrest may be the primary clinical presentation. Once the prolactinoma is diagnosed, medical therapy should be the primary approach to control PRL levels and reduce tumor size. For patients who are not candidates for DA therapy, surgery is the best choice because of its low mortality and high cure rates. With full attention paid during surgery to pituitary protection, hypopituitarism is a rare postoperative complication and can be readily managed. Radiotherapy should be limited because of the high risk of neurological damage and hypopituitarism.
